Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Completed · Phase 2 · Has a placebo group
Conditions studied: Polycythemia Vera
In brief
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.
Key facts
- Study ID
- NCT04057040
- Run by
- Protagonist Therapeutics, Inc.
- People needed
- 70
- Starts
- 2019-10-01
- Expected to finish
- 2024-06-17
- Last updated by the study team
- 2025-08-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic - Mayo Clinic Hospital — Phoenix, Arizona, United States
- Marin Cancer Care — Greenbrae, California, United States
- Stanford University — Palo Alto, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Kansas — Westwood, Kansas, United States
- Pontchartrain Cancer Care — Covington, Louisiana, United States
- Center for Cancer and Blood Disorders — Bethesda, Maryland, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Karmanos Cancer Center — Detroit, Michigan, United States
- Mount Sinai — New York, New York, United States
- New York Presbyterian Hospital - Weill Cornell Medical Center — New York, New York, United States
- Cleveland Clinic - Taussig Cancer Center — Cleveland, Ohio, United States
- Mary Crowley Cancer Research Center — Dallas, Texas, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Sahyadri Super Specialty Hospital — Pune, Maharashtra, India
- All India Institute of Medical Sciences — Rishikesh, Uttarakhand, India
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.